StockData
GH Research PLC logo

GH Research PLC (GHRS) stock

GHRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 5, 2026Score 1/30
$18.75−0.35 (-1.83%)

Close on Nov 16, 2026Market cap $1.16BP/E –Yield –

GH Research ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

GH Research's ebitda for the twelve months ending Jun 30, 2026 was -$71.13M. For fiscal 2025 it was -$60.38M. The highest annual figure on record is -$310.00K in fiscal 2019.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$60.38M–
FY2024Dec 31, 2024-$50.00M–
FY2023Dec 31, 2023-$40.91M–
FY2022Dec 31, 2022-$30.51M–
FY2021Dec 31, 2021-$15.08M–
FY2020Dec 31, 2020-$446.00K–
FY2019Dec 31, 2019-$310.00K–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$19.36M–
Q1 FY2026Mar 31, 2026-$18.66M–
Q4 FY2025Dec 31, 2025-$16.63M–
Q3 FY2025Sep 30, 2025-$16.48M–
Q2 FY2025Jun 30, 2025-$14.62M–
Q1 FY2025Mar 31, 2025-$12.66M–
Q4 FY2024Dec 31, 2024-$12.87M–
Q3 FY2024Sep 30, 2024-$12.54M–
Q2 FY2024Jun 30, 2024-$13.14M–
Q1 FY2024Mar 31, 2024-$11.45M–
Q4 FY2023Dec 31, 2023-$11.08M–
Q3 FY2023Sep 30, 2023-$9.64M–
Q2 FY2023Jun 30, 2023-$9.85M–
Q1 FY2023Mar 31, 2023-$10.34M–
Q4 FY2022Dec 31, 2022-$9.16M–
Q3 FY2022Sep 30, 2022-$6.61M–

More GH Research figures

See a number that looks wrong?